The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture of chemicals and pharmaceuticals Manufacture of basic pharmaceutical products and pharmaceutical preparations 21.10 - Manufacture of basic pharmaceutical products
194 jobs Number of planned job losses
Announcement Date
31 December 2024
Employment effect (start)
1 June 2025
Foreseen end date
31 December 2027
Description
The Swiss pharmaceutical group, Novartis, is set to cut 144 permanent jobs at its manufacturing site in Huningue by the end of 2027. According to trade unionists, the company is reducing its French workforce because the government is reimbursing medicines less and less. Instead, it is investing in Austria. Before negotiations take place to reach agreements on voluntary departures, the trade unions are waiting for a report by experts. In 2024, the company had cut 50 of its prior 800 workforce as it aimed to reduce costs.
Several prior large restructuring have been recorded in ERM database with 170 cuts in Belgium Novartis 2025 - BE.
Eurofound (2024), Novarti, Internal restructuring in France, factsheet number 202912, European Restructuring Monitor. Dublin, https://dev.eurofound.europa.eu/restructuring-events/detail/202912.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
